Cite
Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency?
MLA
Čechová, Anna, et al. “Should Patients with Phosphomannomutase 2-CDG (PMM2-CDG) Be Screened for Adrenal Insufficiency?” Molecular Genetics and Metabolism, vol. 133, no. 4, Aug. 2021, pp. 397–99. EBSCOhost, https://doi.org/10.1016/j.ymgme.2021.06.003.
APA
Čechová, A., Honzík, T., Edmondson, A. C., Ficicioglu, C., Serrano, M., Barone, R., De Lonlay, P., Schiff, M., Witters, P., Lam, C., Patterson, M., Janssen, M. C. H., Correia, J., Quelhas, D., Sykut-Cegielska, J., Plotkin, H., Morava, E., & Sarafoglou, K. (2021). Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screened for adrenal insufficiency? Molecular Genetics and Metabolism, 133(4), 397–399. https://doi.org/10.1016/j.ymgme.2021.06.003
Chicago
Čechová, Anna, Tomáš Honzík, Andrew C Edmondson, Can Ficicioglu, Mercedes Serrano, Rita Barone, Pascale De Lonlay, et al. 2021. “Should Patients with Phosphomannomutase 2-CDG (PMM2-CDG) Be Screened for Adrenal Insufficiency?” Molecular Genetics and Metabolism 133 (4): 397–99. doi:10.1016/j.ymgme.2021.06.003.